fbpx An interview with Dr Pernille Farahna Harees on important management issues in schizophrenia | Progress In Mind

An interview with Dr Pernille Farahna Harees on important management issues in schizophrenia

An interview with Dr Pernille Farahna Harees of the University Hospital, Aarhus, Denmark about how to approach giving a patient the diagnosis of schizophrenia, quality of life and autonomy issues and the place of long-acting injectables

Q: How do you approach giving a patient the diagnosis of schizophrenia?

A: This obviously has a major impact since patients fear being unable to live a normal life. After a thorough evaluation it is sometimes clear from the symptoms that a first-episode patient has schizophrenia, especially if that patient has been ill for a long time. In others, the diagnosis would be made later in the course of the disease.

Q: What does autonomy and quality of life look like for your patients?

A: We try to involve patients in their treatment. Close relatives are also invited to take part. Sometimes they are present when we give the diagnosis, in other cases later in the course of our contact. There will also be a professional carer in the community.

Quality of life depends on how well the illness is managed. If well, there are few relapses and patients can function in the community. Some study, some work at least to some extent.

Q: Can long-acting injectables (LAIs) play a role in achieving these goals?

A: We try to recommend them but find a lot of patients are not ready after their first episode. They feel pills will work OK. My experience is that it often takes a relapse or two before they are motivated to have an LAI.

Early and integrated intervention is important, with family and professional caregivers involved in an active partnership with us. They encourage patients to keep appointments and can identify early signs of relapse.  Education is part of that process.

Q: And what has made the greatest difference in the last ten years?

Joint treatment with caregivers; education about schizophrenia; and medication. 

The views and opinions expressed on this page do not necessarily reflect those of Otsuka and Lundbeck.
You are leaving Progress in Mind
Le informazioni contenute nel nuovo sito prescelto possono non essere conformi al D.Ivo 219/06 che regola la pubblicità dei medicinali per uso umano e le opinioni espresse non riflettono necessariamente le posizioni dell’azienda, non sono da essa avvallate.
Accesso riservato a Operatori Sanitari
Per accedere si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi
L’accesso a Progress in Mind Italia è consentito unicamente agli Operatori Sanitari (medici e farmacisti). I contenuti di questo sito sono prodotti da un team di Operatori Sanitari il cui obiettivo è presentare le ultime novità in ambito psichiatrico e neurologico, attraverso interviste, registrazioni audio/video di seminari con opinion leader, report e sintesi di congressi sia internazionali che nazionali. Per poter accedere al sito è quindi necessario registrarsi e fornire alcuni dati così da poter verificare che l‘utente sia un Operatore Sanitario.
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country